JNJ

187.6

-0.73%↓

ABT

123.23

-0.28%↓

TMO

556.36

-2.05%↓

ISRG

531.87

-0.47%↓

DHR

213.25

-1.1%↓

JNJ

187.6

-0.73%↓

ABT

123.23

-0.28%↓

TMO

556.36

-2.05%↓

ISRG

531.87

-0.47%↓

DHR

213.25

-1.1%↓

JNJ

187.6

-0.73%↓

ABT

123.23

-0.28%↓

TMO

556.36

-2.05%↓

ISRG

531.87

-0.47%↓

DHR

213.25

-1.1%↓

JNJ

187.6

-0.73%↓

ABT

123.23

-0.28%↓

TMO

556.36

-2.05%↓

ISRG

531.87

-0.47%↓

DHR

213.25

-1.1%↓

JNJ

187.6

-0.73%↓

ABT

123.23

-0.28%↓

TMO

556.36

-2.05%↓

ISRG

531.87

-0.47%↓

DHR

213.25

-1.1%↓

Inicio・Lista de Acciones・Avita Therapeutics Inc

Avita Therapeutics Inc

Abierto

3.69 -3.15

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

3.66

Máximo

3.81

Métricas clave
By Trading Economics
Ingresos	3.9M -9.9M
Ventas	-96K 18M
Margen de beneficios	-53.86
Empleados	260
EBITDA	4M -8.1M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+93.8% upside

Dividendos
By Dow Jones
Próximas Ganancias	6 nov 2025

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-39M 102M
Apertura anterior	6.84
Cierre anterior	3.69

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

8.83 / 9.77 Soporte y Resistencia

Avita Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

2 nov 2025, 22:13 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2 nov 2025, 21:23 UTC

Ganancias

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2 nov 2025, 23:43 UTC

Charlas de Mercado

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2 nov 2025, 23:34 UTC

Charlas de Mercado

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2 nov 2025, 21:00 UTC

Ganancias

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2 nov 2025, 20:55 UTC

Ganancias

Westpac FY Business Lending Up 15% on Year>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2 nov 2025, 20:46 UTC

Ganancias

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2 nov 2025, 20:45 UTC

Ganancias

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2 nov 2025, 20:44 UTC

Ganancias

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2 nov 2025, 20:43 UTC

Ganancias

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2 nov 2025, 20:42 UTC

Ganancias

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2 nov 2025, 20:41 UTC

Ganancias

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2 nov 2025, 20:40 UTC

Ganancias

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2 nov 2025, 20:39 UTC

Ganancias

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2 nov 2025, 20:37 UTC

Ganancias

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2 nov 2025, 20:36 UTC

Ganancias

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2 nov 2025, 20:35 UTC

Ganancias

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2 nov 2025, 20:34 UTC

Ganancias

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2 nov 2025, 20:33 UTC

Ganancias

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2 nov 2025, 14:27 UTC

Ganancias

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2 nov 2025, 14:25 UTC

Ganancias

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Comparación entre iguales

Cambio de precio

Avita Therapeutics Inc previsión

Precio Objetivo

By TipRanks

93.8% repunte

Estimación a 12 Meses

Media 7.5 USD 93.8%

Máximo 14 USD

Mínimo 3 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avita Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Avita Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

8.83 / 9.77Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.